FDA Finally Admits That Drugs for Crohn’s Disease and Arthritis May Promote Cancer
Posted Aug 12 2010 11:55am
The FDA has ordered makers of drugs for a variety of inflammatory diseases to add a “black box warning” about an increased risk of cancer in children and adolescents.
A black box warning is the most severe warning that the FDA can place on a product without withdrawing it from the market.
The FDA began analyzing the drugs, known as tumor necrosis factor (TNF) blockers, when reports emerged that dozens of children had developed cancer while taking the drugs. TNF blockers are used to treat inflammatory and autoimmune diseases such as Crohn’s disease and rheumatoid arthritis. They include adalimumab (marketed as Humira), certolizumab pegol (marketed as Cimzia), etanercept (marketed as Enbrel), golimumab (marketed as Simponi) and infliximab (marketed as Remicade.
“FDA announced that it has completed its analysis of TNF blockers and has concluded that there is an increased risk of lymphoma and other cancers associated with the use of these drugs in children and adolescents,” spokesperson Crystal Rice said . “This new safety information is now being added to the boxed warning for these products.”
The drugs already carry warnings about the risk of fungal infections and other side effects.
Since people with the inflammatory diseases that TNF blockers treat are already at an increased risk of cancer, those who take the drugs are at particularly high risk.